HMOX1 POLYMORPHISMS AS PROGNOSTIC PREDICTORS FOR PROSTATE CANCER IN ARGENTINIAN POPULATION

GASTON PASCUAL; AGUSTINA SABATER; ROCIO SENIUK; AYELEN TORO; OSVALDO MAZZA; ELBA VAZQUEZ; GERALDINE GUERON; JAVIER COTIGNOLA

Congreso; LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; 2022

Heme Oxygenase 1 (HO-1), the rate-limiting enzyme in heme degradation and encoded by HMOX1 gene, has a strong anti-tumoral effect in prostate cancer. HMOX1 expression levels are modulated by the length of a dinucleotide (GT)n microsatellite polymorphism mapping in its promoter region. Prostate cancer is the second most incident cancer in men and the sixth leading cause of cancer-related deaths in men worldwide. Nowadays, one of the strongest predictors for newly diagnosed prostate cancer is the Gleason score, a histopathology-based classification system. However, Gleason score presents diverse limitations in capturing tumoral heterogeneity; thus, hindering accurate disease diagnosis. Consequently, the establishment of novel biomarkers is important to improve prostate cancer prognosis. In this work we genotyped the (GT)n promoter polymorphisms in the HMOX1 gene and analyze its association with prostate cancer clinicopathological parameters. We studied 108 peripheral blood mononuclear cells (PBMC) samples from prostate cancer patients from Hospital de Clínicas “Jose de San Martín”. Genomic DNA was extracted and the (GT)n was genotyped by fluorescent PCR and capillary electrophoresis. Sanger sequencing was performed to validate the results in random selected samples. The length of the (GT)n varied from 11 to 40 repeats. HMOX1 genotypes were stratified as “Long allele (L)” (≥29 repeats), or “Short allele (S)” (